Fig. 2From: Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancerProgression-free survival (PFS) (a) and overall survival (OS) (b) of patients treated with gemcitabine and oxaliplatin (GEMOX) alone or GEMOX with erlotinib (GEMOXT)Back to article page